{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T14:15:19Z","timestamp":1790864119471,"version":"4.1.0"},"reference-count":32,"publisher":"Springer Science and Business Media LLC","issue":"3","license":[{"start":{"date-parts":[[2021,1,12]],"date-time":"2021-01-12T00:00:00Z","timestamp":1610409600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2021,1,12]],"date-time":"2021-01-12T00:00:00Z","timestamp":1610409600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Arch Gynecol Obstet"],"published-print":{"date-parts":[[2021,3]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:sec>\n                <jats:title>Purpose<\/jats:title>\n                <jats:p>Progestin-primed ovarian stimulation (PPOS) is a new ovarian stimulation protocol that has been used over the last decade to enhance reproductive function. The purpose of this study is to evaluate whether PPOS is as effective as conventional protocols (without GnRHa downregulation).<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Method<\/jats:title>\n                <jats:p>Search terms included \u201cmedroxyprogesterone\u201d, \u201cdydrogesterone\u201d, \u201cprogestin-primed ovarian stimulation\u201d, \u201cPPOS\u201d, \u201coocyte retrieval\u201d, \u201cin vitro fertilization\u201d, \u201cIVF\u201d, \u201cICSI\u201d, \u201cART\u201d, and \u201creproductive\u201d. The selection criteria were nonrandomized studies and randomized controlled studies. For data collection and analysis, the Review Manager software, Newcastle\u2013Ottowa Quality Assessment Scale and GRADE approach were used.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Results<\/jats:title>\n                <jats:p>The clinical pregnancy rates were not significantly different in either RCTs or NRCTs [RR 0.96, 95% CI (0.69\u20131.33), <jats:italic>I<\/jats:italic><jats:sup>2<\/jats:sup>\u2009=\u200971%, <jats:italic>P<\/jats:italic>\u2009=\u20090.81]; [RR 0.99, 95% CI (0.83\u20131.17), <jats:italic>I<\/jats:italic><jats:sup>2<\/jats:sup>\u2009=\u200938%, <jats:italic>P<\/jats:italic>\u2009=\u20090.88]. The live birth rates of RCTs and NRCTs did not differ [RCT: RR 1.08, 95% CI (0.74, 1.57), <jats:italic>I<\/jats:italic><jats:sup>2<\/jats:sup>\u2009=\u200966%, <jats:italic>P<\/jats:italic>\u2009=\u20090.69; NRCT: OR 1.03 95% CI 0.84\u20131.26), <jats:italic>I<\/jats:italic><jats:sup>2<\/jats:sup>\u2009=\u200950%, <jats:italic>P<\/jats:italic>\u2009=\u20090.79]. The PPOS protocol had a lower rate of OHSS [RR 0.52, 95% CI (0.36\u20130.75), <jats:italic>I<\/jats:italic><jats:sup>2<\/jats:sup>\u2009=\u20090%, <jats:italic>P<\/jats:italic>\u2009=\u20090.0006]. The secondary results showed that compared to the control protocol, the endometrium was thicker [95% CI (0.00\u20130.78), <jats:italic>I<\/jats:italic><jats:sup>2<\/jats:sup>\u2009=\u20090%, <jats:italic>P<\/jats:italic>\u2009=\u20090.05], the number of obtained embryos was higher [95% CI (0.04\u20130.65), <jats:italic>I<\/jats:italic><jats:sup>2<\/jats:sup>\u2009=\u200917%, <jats:italic>P<\/jats:italic>\u2009=\u20090.03] and more hMG was needed [in NRCT: 95% CI (307.44, 572.73), <jats:italic>I<\/jats:italic><jats:sup>2<\/jats:sup>\u2009=\u20090%, <jats:italic>P<\/jats:italic>\u2009&lt;\u20090.00001] with the PPOS protocol.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Conclusion<\/jats:title>\n                <jats:p>The PPOS protocol produces more obtained embryos and a thicker endometrium than the control protocol, with a lower rate of OHSS and an equal live birth rate. The PPOS protocol could be a safe option as a personalized protocol for infertile patients.\n<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Trial registration<\/jats:title>\n                <jats:p>Registration at PROSPERO: CRD42020176577.<\/jats:p>\n              <\/jats:sec>","DOI":"10.1007\/s00404-020-05939-y","type":"journal-article","created":{"date-parts":[[2021,1,13]],"date-time":"2021-01-13T13:02:32Z","timestamp":1610542952000},"page":"615-630","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":39,"title":["Effectiveness of progesterone-primed ovarian stimulation in assisted reproductive technology: a systematic review and meta-analysis"],"prefix":"10.1007","volume":"303","author":[{"given":"Ling","family":"Cui","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yonghong","family":"Lin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9543-7675","authenticated-orcid":false,"given":"Fang","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chen","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2021,1,12]]},"reference":[{"issue":"1","key":"5939_CR1","doi-asserted-by":"publisher","first-page":"62","DOI":"10.1016\/j.fertnstert.2015.03.022","volume":"104","author":"Y Kuang","year":"2015","unstructured":"Kuang Y, Chen Q, Fu Y, Wang Y, Hong Q, Lyu Q et al (2015) Medroxyprogesterone acetate is an effective oral alternative for preventing premature luteinizing hormone surges in women undergoing controlled ovarian hyperstimulation for in vitro fertilization. Fertil Steril 104(1):62\u2013703. https:\/\/doi.org\/10.1016\/j.fertnstert.2015.03.022","journal-title":"Fertil Steril"},{"key":"5939_CR2","doi-asserted-by":"publisher","first-page":"4461","DOI":"10.2147\/DDDT.S230129","volume":"13","author":"J Huang","year":"2019","unstructured":"Huang J, Xie Q, Lin J, Lu X, Zhu J, Gao H et al (2019) Progestin-primed ovarian stimulation with dydrogesterone versus medroxyprogesterone acetate in women with polycystic ovarian syndrome for in vitro fertilization: a retrospective cohort study. Drug Design, Dev Therapy 13:4461\u20134470. https:\/\/doi.org\/10.2147\/DDDT.S230129","journal-title":"Drug Design, Dev Therapy"},{"issue":"3","key":"5939_CR3","doi-asserted-by":"publisher","first-page":"663","DOI":"10.1007\/s00404-018-4856-8","volume":"298","author":"N Iwami","year":"2018","unstructured":"Iwami N, Kawamata M, Ozawa N, Yamamoto T, Watanabe E, Moriwaka O et al (2018) New trial of progestin-primed ovarian stimulation using dydrogesterone versus a typical GnRH antagonist regimen in assisted reproductive technology. Arch Gynecol Obstet 298(3):663\u2013671. https:\/\/doi.org\/10.1007\/s00404-018-4856-8","journal-title":"Arch Gynecol Obstet"},{"issue":"9","key":"5939_CR4","doi-asserted-by":"publisher","first-page":"671","DOI":"10.18502\/ijrm.v17i9.5103","volume":"17","author":"M Eftekhar","year":"2019","unstructured":"Eftekhar M, Hoseini M, Saeed L (2019) Progesterone-primed ovarian stimulation in polycystic ovarian syndrome: an RCT. Int J Reprod Biomed 17(9):671\u2013676. https:\/\/doi.org\/10.18502\/ijrm.v17i9.5103","journal-title":"Int J Reprod Biomed"},{"issue":"1","key":"5939_CR5","doi-asserted-by":"publisher","first-page":"91","DOI":"10.1186\/s12958-019-0518-3","volume":"17","author":"Q Peng","year":"2019","unstructured":"Peng Q, Cao X, Wang J, Wang L, Xu J, Ji X et al (2019) Progestin-primed ovarian stimulation vs mild stimulation in women with advanced age above 40: a retrospective cohort study. Reprod Biol Endocrinol: RB&E 17(1):91. https:\/\/doi.org\/10.1186\/s12958-019-0518-3","journal-title":"Reprod Biol Endocrinol: RB&E"},{"issue":"5","key":"5939_CR6","doi-asserted-by":"publisher","first-page":"1520","DOI":"10.1016\/j.fertnstert.2009.09.009","volume":"92","author":"F Zegers-Hochschild","year":"2009","unstructured":"Zegers-Hochschild F, Adamson GD, de Mouzon J, Ishihara O, Mansour R, Nygren K et al (2009) International Committee for Monitoring Assisted Reproductive Technology (ICMART) and the World Health Organization (WHO) revised glossary of ART terminology, 2009. Fertil Steril 92(5):1520\u20131524. https:\/\/doi.org\/10.1016\/j.fertnstert.2009.09.009","journal-title":"Fertil Steril"},{"key":"5939_CR7","doi-asserted-by":"publisher","first-page":"796","DOI":"10.3389\/fendo.2019.00796","volume":"10","author":"Q Chen","year":"2019","unstructured":"Chen Q, Chai W, Wang Y, Cai R, Zhang S, Lu X et al (2019) Progestin vs. Gonadotropin-releasing hormone antagonist for the prevention of premature luteinizing hormone surges in poor responders undergoing in vitro fertilization treatment: a randomized controlled trial. Front Endocrinol 10:796. https:\/\/doi.org\/10.3389\/fendo.2019.00796","journal-title":"Front Endocrinol"},{"issue":"5","key":"5939_CR8","doi-asserted-by":"publisher","first-page":"872","DOI":"10.1093\/humrep\/dez034","volume":"34","author":"R Begueria","year":"2019","unstructured":"Begueria R, Garcia D, Vassena R, Rodriguez A (2019) Medroxyprogesterone acetate versus ganirelix in oocyte donation: a randomized controlled trial. Hum Reprod 34(5):872\u2013880. https:\/\/doi.org\/10.1093\/humrep\/dez034","journal-title":"Hum Reprod"},{"issue":"2","key":"5939_CR9","doi-asserted-by":"publisher","first-page":"99","DOI":"10.1016\/j.jogoh.2018.10.008","volume":"48","author":"P Huang","year":"2019","unstructured":"Huang P, Tang M, Qin A (2019) Progestin-primed ovarian stimulation is a feasible method for poor ovarian responders undergoing in IVF\/ICSI compared to a GnRH antagonist protocol: a retrospective study. J Gynecol Obstet Human Reprod 48(2):99\u2013102. https:\/\/doi.org\/10.1016\/j.jogoh.2018.10.008","journal-title":"J Gynecol Obstet Human Reprod"},{"issue":"4","key":"5939_CR10","doi-asserted-by":"publisher","first-page":"677","DOI":"10.1016\/j.fertnstert.2019.06.009","volume":"112","author":"S Yildiz","year":"2019","unstructured":"Yildiz S, Turkgeldi E, Angun B, Eraslan A, Urman B, Ata B (2019) Comparison of a novel flexible progestin primed ovarian stimulation protocol and the flexible gonadotropin-releasing hormone antagonist protocol for assisted reproductive technology. Fertil Steril 112(4):677\u2013683. https:\/\/doi.org\/10.1016\/j.fertnstert.2019.06.009","journal-title":"Fertil Steril"},{"issue":"1","key":"5939_CR11","doi-asserted-by":"publisher","first-page":"18","DOI":"10.1186\/s13048-020-00620-z","volume":"13","author":"E Mathieu d\u2019Argent","year":"2020","unstructured":"Mathieu d\u2019Argent E, Ferrier C, Zacharopoulou C, Ahdad-Yata N, Boudy AS, Cantalloube A et al (2020) Outcomes of fertility preservation in women with endometriosis: comparison of progestin-primed ovarian stimulation versus antagonist protocols. J Ovarian Res 13(1):18. https:\/\/doi.org\/10.1186\/s13048-020-00620-z","journal-title":"J Ovarian Res"},{"key":"5939_CR12","doi-asserted-by":"publisher","first-page":"3357","DOI":"10.12659\/MSM.906602","volume":"24","author":"X Wen","year":"2018","unstructured":"Wen X, Kuang Y, Zhou L, Yu B, Chen Q, Fu Y et al (2018) Lipidomic components alterations of human follicular fluid reveal the relevance of improving clinical outcomes in women using progestin-primed ovarian stimulation compared to short-term protocol. Med Sci Monitor: Int Med J Exp Clin Res 24:3357\u20133365. https:\/\/doi.org\/10.12659\/MSM.906602","journal-title":"Med Sci Monitor: Int Med J Exp Clin Res"},{"issue":"34","key":"5939_CR13","doi-asserted-by":"publisher","first-page":"e11906","DOI":"10.1097\/MD.0000000000011906","volume":"97","author":"N Wang","year":"2018","unstructured":"Wang N, Lin J, Zhu Q, Fan Y, Wang Y, Fu Y et al (2018) Comparison of neonatal outcomes and live-birth defects after progestin-primed ovarian stimulation versus conventional ovarian stimulation for in vitro fertilization: a large retrospective cohort study. Medicine 97(34):e11906. https:\/\/doi.org\/10.1097\/MD.0000000000011906","journal-title":"Medicine"},{"issue":"6","key":"5939_CR14","doi-asserted-by":"publisher","first-page":"1356","DOI":"10.1016\/j.fertnstert.2016.07.1068","volume":"106","author":"X Lu","year":"2016","unstructured":"Lu X, Hong Q, Sun L, Chen Q, Fu Y, Ai A et al (2016) Dual trigger for final oocyte maturation improves the oocyte retrieval rate of suboptimal responders to gonadotropin-releasing hormone agonist. Fertil Steril 106(6):1356\u20131362. https:\/\/doi.org\/10.1016\/j.fertnstert.2016.07.1068","journal-title":"Fertil Steril"},{"issue":"9","key":"5939_CR15","doi-asserted-by":"publisher","first-page":"e2939","DOI":"10.1097\/MD.0000000000002939","volume":"95","author":"Y Wang","year":"2016","unstructured":"Wang Y, Chen Q, Wang N, Chen H, Lyu Q, Kuang Y (2016) Controlled ovarian stimulation using medroxyprogesterone acetate and hMG in patients with polycystic ovary syndrome treated for IVF: a double-blind randomized crossover clinical trial. Medicine 95(9):e2939. https:\/\/doi.org\/10.1097\/MD.0000000000002939","journal-title":"Medicine"},{"issue":"5","key":"5939_CR16","doi-asserted-by":"publisher","first-page":"691","DOI":"10.1016\/j.rbmo.2018.12.044","volume":"38","author":"MB Evans","year":"2019","unstructured":"Evans MB, Parikh T, DeCherney AH, Csokmay JM, Healy MW, Hill MJ (2019) Evaluation of the cost-effectiveness of ovulation suppression with progestins compared with GnRH analogs in assisted reproduction cycles. Reprod Biomed Online 38(5):691\u2013698. https:\/\/doi.org\/10.1016\/j.rbmo.2018.12.044","journal-title":"Reprod Biomed Online"},{"issue":"10","key":"5939_CR17","doi-asserted-by":"publisher","first-page":"e1","DOI":"10.1016\/j.jclinepi.2009.06.006","volume":"62","author":"A Liberati","year":"2009","unstructured":"Liberati A, Altman DG, Tetzlaff J, Mulrow C, Gotzsche PC, Ioannidis JP et al (2009) The PRISMA statement for reporting systematic reviews and meta-analyses of studies that evaluate health care interventions: explanation and elaboration. J Clin Epidemiol 62(10):e1-34. https:\/\/doi.org\/10.1016\/j.jclinepi.2009.06.006","journal-title":"J Clin Epidemiol"},{"key":"5939_CR18","doi-asserted-by":"publisher","first-page":"d5928","DOI":"10.1136\/bmj.d5928","volume":"343","author":"JP Higgins","year":"2011","unstructured":"Higgins JP, Altman DG, Gotzsche PC, Juni P, Moher D, Oxman AD et al (2011) The Cochrane Collaboration\u2019s tool for assessing risk of bias in randomised trials. BMJ 343:d5928. https:\/\/doi.org\/10.1136\/bmj.d5928","journal-title":"BMJ"},{"key":"5939_CR19","unstructured":"Wells GA SB, O\u2019Connell Dea (2008) The Newcastle-Ottawa Scale (NOS) for assessing the quality of nonrandomised studies in meta-analyses. http:\/\/www.ohrica\/programs\/clinical_epidemiology\/oxfordasp"},{"issue":"8","key":"5939_CR20","doi-asserted-by":"publisher","first-page":"1067","DOI":"10.1097\/ACM.0000000000000786","volume":"90","author":"DA Cook","year":"2015","unstructured":"Cook DA, Reed DA (2015) Appraising the quality of medical education research methods: the Medical Education Research Study Quality Instrument and the Newcastle-Ottawa Scale-Education. Acad Med: J Assoc Am Med Colleges 90(8):1067\u20131076. https:\/\/doi.org\/10.1097\/ACM.0000000000000786","journal-title":"Acad Med: J Assoc Am Med Colleges"},{"issue":"7650","key":"5939_CR21","doi-asserted-by":"publisher","first-page":"924","DOI":"10.1136\/bmj.39489.470347.AD","volume":"336","author":"GH Guyatt","year":"2008","unstructured":"Guyatt GH, Oxman AD, Vist GE, Kunz R, Falck-Ytter Y, Alonso-Coello P et al (2008) GRADE: an emerging consensus on rating quality of evidence and strength of recommendations. BMJ 336(7650):924\u2013926. https:\/\/doi.org\/10.1136\/bmj.39489.470347.AD","journal-title":"BMJ"},{"issue":"11","key":"5939_CR22","doi-asserted-by":"publisher","first-page":"1539","DOI":"10.1002\/sim.1186","volume":"21","author":"JP Higgins","year":"2002","unstructured":"Higgins JP, Thompson SG (2002) Quantifying heterogeneity in a meta-analysis. Stat Med 21(11):1539\u20131558. https:\/\/doi.org\/10.1002\/sim.1186","journal-title":"Stat Med"},{"issue":"1","key":"5939_CR23","doi-asserted-by":"publisher","first-page":"81","DOI":"10.1016\/s1472-6483(10)60559-7","volume":"16","author":"HG Al-Inany","year":"2008","unstructured":"Al-Inany HG, Abou-Setta AM, Aboulghar MA, Mansour RT, Serour GI (2008) Efficacy and safety of human menopausal gonadotrophins versus recombinant FSH: a meta-analysis. Reprod Biomed Online 16(1):81\u201388. https:\/\/doi.org\/10.1016\/s1472-6483(10)60559-7","journal-title":"Reprod Biomed Online"},{"issue":"2","key":"5939_CR24","doi-asserted-by":"publisher","first-page":"310","DOI":"10.1093\/humrep\/dem305","volume":"23","author":"A Coomarasamy","year":"2008","unstructured":"Coomarasamy A, Afnan M, Cheema D, van der Veen F, Bossuyt PM, van Wely M (2008) Urinary hMG versus recombinant FSH for controlled ovarian hyperstimulation following an agonist long down-regulation protocol in IVF or ICSI treatment: a systematic review and meta-analysis. Hum Reprod 23(2):310\u2013315. https:\/\/doi.org\/10.1093\/humrep\/dem305","journal-title":"Hum Reprod"},{"issue":"7","key":"5939_CR25","doi-asserted-by":"publisher","first-page":"1471","DOI":"10.1007\/s10815-019-01486-x","volume":"36","author":"AR Jesus","year":"2019","unstructured":"Jesus AR, Silva-Soares S, Silva J, Severo M, Barros A, Doria S (2019) Reproductive success of assisted reproductive technology in couples with chromosomal abnormalities. J Assist Reprod Genet 36(7):1471\u20131479. https:\/\/doi.org\/10.1007\/s10815-019-01486-x","journal-title":"J Assist Reprod Genet"},{"issue":"6","key":"5939_CR26","doi-asserted-by":"publisher","first-page":"1207","DOI":"10.1007\/s00404-017-4537-z","volume":"296","author":"J Zhang","year":"2017","unstructured":"Zhang J, Mao X, Wang Y, Chen Q, Lu X, Hong Q et al (2017) Neonatal outcomes and congenital malformations in children born after human menopausal gonadotropin and medroxyprogesterone acetate treatment cycles. Arch Gynecol Obstet 296(6):1207\u20131217. https:\/\/doi.org\/10.1007\/s00404-017-4537-z","journal-title":"Arch Gynecol Obstet"},{"key":"5939_CR27","doi-asserted-by":"publisher","first-page":"2553","DOI":"10.2147\/DDDT.S210228","volume":"13","author":"J Huang","year":"2019","unstructured":"Huang J, Xie Q, Lin J, Lu X, Wang N, Gao H et al (2019) Neonatal outcomes and congenital malformations in children born after dydrogesterone application in progestin-primed ovarian stimulation protocol for IVF: a retrospective cohort study. Drug Design, Dev Therapy 13:2553\u20132563. https:\/\/doi.org\/10.2147\/DDDT.S210228","journal-title":"Drug Design, Dev Therapy"},{"issue":"2","key":"5939_CR28","doi-asserted-by":"publisher","first-page":"229","DOI":"10.1093\/humrep\/dex367","volume":"33","author":"S Yu","year":"2018","unstructured":"Yu S, Long H, Chang HY, Liu Y, Gao H, Zhu J et al (2018) New application of dydrogesterone as a part of a progestin-primed ovarian stimulation protocol for IVF: a randomized controlled trial including 516 first IVF\/ICSI cycles. Hum Reprod 33(2):229\u2013237. https:\/\/doi.org\/10.1093\/humrep\/dex367","journal-title":"Hum Reprod"},{"issue":"21","key":"5939_CR29","doi-asserted-by":"publisher","first-page":"e909","DOI":"10.1097\/MD.0000000000000909","volume":"94","author":"X Zhu","year":"2015","unstructured":"Zhu X, Zhang X, Fu Y (2015) Utrogestan as an effective oral alternative for preventing premature luteinizing hormone surges in women undergoing controlled ovarian hyperstimulation for in vitro fertilization. Medicine 94(21):e909. https:\/\/doi.org\/10.1097\/MD.0000000000000909","journal-title":"Medicine"},{"issue":"1","key":"5939_CR30","doi-asserted-by":"publisher","first-page":"455","DOI":"10.1186\/s13063-018-2850-x","volume":"19","author":"Y Wang","year":"2018","unstructured":"Wang Y, Kuang Y, Chen Q, Cai R (2018) Gonadotropin-releasing hormone antagonist versus progestin for the prevention of premature luteinising hormone surges in poor responders undergoing in vitro fertilisation treatment: study protocol for a randomised controlled trial. Trials 19(1):455. https:\/\/doi.org\/10.1186\/s13063-018-2850-x","journal-title":"Trials"},{"issue":"5","key":"5939_CR31","doi-asserted-by":"publisher","first-page":"497","DOI":"10.1007\/s40618-014-0204-4","volume":"38","author":"PE Levi Setti","year":"2015","unstructured":"Levi Setti PE, Alviggi C, Colombo GL, Pisanelli C, Ripellino C, Longobardi S et al (2015) Human recombinant follicle stimulating hormone (rFSH) compared to urinary human menopausal gonadotropin (HMG) for ovarian stimulation in assisted reproduction: a literature review and cost evaluation. J Endocrinol Invest 38(5):497\u2013503. https:\/\/doi.org\/10.1007\/s40618-014-0204-4","journal-title":"J Endocrinol Invest"},{"key":"5939_CR32","doi-asserted-by":"publisher","first-page":"77","DOI":"10.1186\/s12958-015-0080-6","volume":"13","author":"A Revelli","year":"2015","unstructured":"Revelli A, Pettinau G, Basso G, Carosso A, Ferrero A, Dallan C et al (2015) Controlled Ovarian Stimulation with recombinant-FSH plus recombinant-LH vs. human Menopausal Gonadotropin based on the number of retrieved oocytes: results from a routine clinical practice in a real-life population. Reprod Biol Endocrinol: RB&E 13:77. https:\/\/doi.org\/10.1186\/s12958-015-0080-6","journal-title":"Reprod Biol Endocrinol: RB&E"}],"container-title":["Archives of Gynecology and Obstetrics"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00404-020-05939-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s00404-020-05939-y\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00404-020-05939-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,3,15]],"date-time":"2021-03-15T15:26:11Z","timestamp":1615821971000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s00404-020-05939-y"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,1,12]]},"references-count":32,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2021,3]]}},"alternative-id":["5939"],"URL":"https:\/\/doi.org\/10.1007\/s00404-020-05939-y","relation":{},"ISSN":["0932-0067","1432-0711"],"issn-type":[{"value":"0932-0067","type":"print"},{"value":"1432-0711","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,1,12]]},"assertion":[{"value":"1 June 2020","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"13 December 2020","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"12 January 2021","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with ethical standards"}},{"value":"None.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}]}}